Codexis, Inc. (NASDAQ: CDXS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $11.00 price target on the stock.
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics [Yahoo! Finance]
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics
Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics [Yahoo! Finance]